PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
Both companies reducing costs. Martin Whitman would check industry efficiency trends.
41.00%
Gross profit growth below 50% of AGEN's 385.58%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-31.86%
R&D reduction while AGEN shows 1854.39% growth. Joel Greenblatt would examine competitive risk.
-15.50%
G&A reduction while AGEN shows 11.99% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.75%
Operating expenses reduction while AGEN shows 337.35% growth. Joel Greenblatt would examine advantage.
-27.36%
Total costs reduction while AGEN shows 24.78% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
D&A reduction while AGEN shows 82.36% growth. Joel Greenblatt would examine efficiency.
28.32%
EBITDA growth below 50% of AGEN's 101.86%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
27.93%
Operating income growth below 50% of AGEN's 90.59%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-5.21%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
29.77%
Pre-tax income growth 1.25-1.5x AGEN's 24.72%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
128.31%
Tax expense growth while AGEN reduces burden. John Neff would investigate differences.
29.77%
Net income growth 1.25-1.5x AGEN's 25.58%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
30.61%
EPS growth 1.25-1.5x AGEN's 24.62%. Bruce Berkowitz would examine sustainability.
30.61%
Diluted EPS growth 1.25-1.5x AGEN's 24.62%. Bruce Berkowitz would examine sustainability.
2.13%
Share count increase while AGEN reduces shares. John Neff would investigate differences.
2.13%
Diluted share increase while AGEN reduces shares. John Neff would investigate differences.